<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03123055</url>
  </required_header>
  <id_info>
    <org_study_id>B-701-U22</org_study_id>
    <secondary_id>2017-001292-23</secondary_id>
    <nct_id>NCT03123055</nct_id>
  </id_info>
  <brief_title>A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma</brief_title>
  <acronym>FIERCE-22</acronym>
  <official_title>A Multi-Center, Open-Label Phase 1b/2 Study of a Novel FGFR3 Inhibitor (B-701) Combined With Pembrolizumab in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma Who Have Progressed Following Platinum-based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioClin Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioClin Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b/2 multi-center, open-label study to establish the initial safety and to
      determine a recommended Phase 2 dose of B-701 in combination with pembrolizumab, and to
      determine safety, tolerability and efficacy of B-701 plus pembrolizumab in the treatment of
      subjects with locally advanced or metastatic UCC, who have progressed following
      platinum-based chemotherapy and who have not received prior immune checkpoint inhibitor
      therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1b/2 multi-center, open-label study to determine the safety, tolerability,
      and efficacy of B-701 plus pembrolizumab in the treatment of subjects with locally advanced
      or metastatic UCC, who have progressed following platinum-based chemotherapy and who have not
      received prior immune checkpoint inhibitor or FGFR inhibitor-targeted therapy. The study
      consists of 2 parts: a Phase 1b lead-in phase enrolling 6 to 18 subjects and a Phase 2 dose
      expansion phase enrolling up to a total of 74 subjects.

      Subjects who discontinue B-701 may continue on study and receive pembrolizumab alone until
      disease progression, death, withdrawal of patient consent, or study termination. Subjects who
      discontinue pembrolizumab may continue on study and receive B-701 alone until disease
      progression, death, withdrawal of patient consent, or study termination.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>B-701 as monotherapy for first 2 weeks followed by B-701 in combination with pembrolizumab thereafter.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Initial safety and determination of recommended Phase 2 dose according to dose-limiting Toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>DLTs within a period of 35 days will be analyzed reviewing the aggregate of adverse events (AEs) and serious adverse events (SAEs) by the B-701 program Safety Oversight Committee and will result in a recommended Phase 2 dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of B-701 plus pembrolizumab</measure>
    <time_frame>2.5 years</time_frame>
    <description>Evaluate the safety and tolerability of B-701 plus pembrolizumab in subjects with UCC as assessed by number of subjects experiencing adverse events (AEs and SAEs), physical examination findings, laboratory test results, and vital signs over time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of B-701 plus pembrolizumab measured by ORR</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluate the efficacy of B-701 plus pembrolizumab in subjects with UCC as measured by objective response rate (ORR) by RECIST 1.1. ORR is defined as the percentage of subjects who have baseline measurable disease and who achieve a best response of either complete response (CR) or partial response (PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of changes in biomarkers induced by B-701</measure>
    <time_frame>2.5 years</time_frame>
    <description>Whole blood (PBMCs), serum, and plasma samples for biomarker analyses will be obtained prior to infusion of B-701 at pre-defined visit days.
The effects of B-701 on the downstream signaling of the FGFR3 pathway, tumor sub-type and on the immune surveillance of UCC tumors will be monitored using techniques that include gene expression profiling (such as whole transcriptome RNAseq), sequencing of T-cell receptors, and immunohistochemistry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of B-701 in combination with pembrolizumab as measured by DOR</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluate the efficacy of B-701 in combination with pembrolizumab in the treatment of subjects with UCC as measured by duration of objective response (DOR), defined as the time from first occurrence of a documented, objective response until the time of relapse or death from any cause (RECIST 1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of B-701 in combination with pembrolizumab as measured by DCR</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluate the efficacy of B-701 in combination with pembrolizumab in the treatment of subjects with UCC as measured by disease control rate (DCR), defined as the percentage of subjects who achieve either complete response (CR) or partial response (PR) or stable disease (SD) according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of B-701 in combination with pembrolizumab as measured by PFS</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluate the efficacy of B-701 in combination with pembrolizumab in the treatment of subjects with UCC as measured by progression-free survival (PFS), defined as the time from a first study treatment dose to first occurrence of disease progression (per RECIST 1.1) or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of B-701 in combination with pembrolizumab as measured by OS</measure>
    <time_frame>2.5 years</time_frame>
    <description>Evaluate the efficacy of B-701 in combination with pembrolizumab in the treatment of subjects with UCC as measured by overall survival (OS), defined as the time from first study drug administration to death from any cause (RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subject reported quality of life</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluate the efficacy of B-701 in combination with pembrolizumab in the treatment of subjects with UCC as measured by the change over time in subject reported quality of life as measured by the European Organization for Research and Treatment Quality of Life Questionnaire (EORTC QLQ-C30).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>PK analysis of B-701</measure>
    <time_frame>2 years</time_frame>
    <description>PK will be analyzed by measuring B-701 C(trough) levels. B-701 C(trough) levels then will be summarized over time throughout the study and will be compared to predicted B-701 C(trough) levels, whose prediction is based on data observed in previous studies with B-701.</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunogenicity of B-701</measure>
    <time_frame>2 years</time_frame>
    <description>Determine the immunogenicity of B-701 as measured by anti-B-701 antibody titers at several time points throughout the study.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Locally Advanced or Metastatic Urothelial Cell Carcinoma</condition>
  <condition>Urinary Bladder Disease</condition>
  <condition>Urological Diseases</condition>
  <arm_group>
    <arm_group_label>B-701</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B-701 (25 mg/kg) will be administered via IV infusion on Cycle 0 Day 1 for a single 14-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-701 plus pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B-701 (25 mg/kg [or the recommended Phase 2 dose if different than 25 mg/kg]) plus pembrolizumab (200 mg) will be administered by IV infusion on Cycle 1 Day 1 once every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B-701</intervention_name>
    <description>B-701 is a human IgG1 monoclonal antibody that is highly specific for the FGFR3 receptor.</description>
    <arm_group_label>B-701</arm_group_label>
    <arm_group_label>B-701 plus pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab is a humanized antibody used in cancer immunotherapy. Pembrolizumab targets and blocks a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells.</description>
    <arm_group_label>B-701 plus pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Have locally advanced (on TNM staging: T4b and any N, or any T and N2-3) or metastatic
             transitional cell carcinoma of the urothelium, including of the urinary bladder,
             urethra, ureter, and/or renal pelvis. The diagnosis must be histologically or
             cytologically confirmed.

          2. Have progression during or following platinum-containing chemotherapy or within 12
             months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

          3. Have available archival tumor or be willing to undergo diagnostic biopsy at screening.
             Sample must be of suitable quality and quantity to satisfy group assignment and
             biomarker endpoints.

          4. Have measurable disease according to Response Evaluation Criteria in Solid Tumors
             Version 1.1 (RECIST v1.1).

          5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1.

        Key Exclusion Criteria:

          1. Participants with a history of idiopathic pulmonary fibrosis, organizing pneumonia,
             drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on
             the Screening chest CT scan.

          2. Prior therapy with an anti-programmed cell death 1 (PD-1) or anti-PD-Ligand 1 agent,
             or with an agent directed to another co-inhibitory T-cell receptor or FGFR inhibitor.

          3. Patients with autoimmune disease or medical conditions that required systemic
             corticosteroids (&gt; 10 mg/day prednisone or its equivalent) or other immunosuppressive
             medications or any other form of systemic immunosuppressive therapy within 7 days
             prior to the first dose of study treatment. Note: Replacement therapy (e.g.
             physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency,
             etc.) is not considered a form of systemic treatment.

          4. Primary central nervous system (CNS) malignancy or CNS metastases.

          5. History of clinically significant coagulation or platelet disorder in the past 12
             months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BioClin Therapeutics</last_name>
    <role>Study Chair</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BioClin Therapeutics</last_name>
    <phone>925-413-6140</phone>
    <email>clin-ops@bioclintherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Therapeutics</last_name>
      <phone>925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brussel</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>+1-925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Team</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>+1-925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Team</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>+1-925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>+1-925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>+1-925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>+1-925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>+1-925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kassel</city>
        <zip>34125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>+1-925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>+1-925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>+1-925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>+1-925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>+1-925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3854</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>+1-925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-514</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>+1-925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warsaw</city>
        <zip>04-125</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>+1-925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>+1-925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wieliszew</city>
        <zip>05-135</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>+1-925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-413</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>+1-925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site 2</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>+1-925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>+1-925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11070</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>+1-925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>+1-925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Niš</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>+1-925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BioClin Study Team</last_name>
      <phone>+1-925-413-6140</phone>
      <email>clin-ops@bioclintherapeutics.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2017</study_first_submitted>
  <study_first_submitted_qc>April 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>February 24, 2018</last_update_submitted>
  <last_update_submitted_qc>February 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urothelial Cell Carcinoma</keyword>
  <keyword>UCC</keyword>
  <keyword>bladder cancer</keyword>
  <keyword>B-701</keyword>
  <keyword>FGFR3</keyword>
  <keyword>invasive bladder cancer</keyword>
  <keyword>Transitional Cell Carcinoma</keyword>
  <keyword>TCC</keyword>
  <keyword>second line therapy</keyword>
  <keyword>monoclonal antibody</keyword>
  <keyword>combination therapy</keyword>
  <keyword>Phase 1b</keyword>
  <keyword>pembrolizumab</keyword>
  <keyword>checkpoint inhibitor</keyword>
  <keyword>Phase 2</keyword>
  <keyword>Urothelial Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Urinary Bladder Diseases</mesh_term>
    <mesh_term>Urologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

